Author

D. Dupere-Richer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Assay:ChIP-seq· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2

Frequent Co-Authors

J. D. Licht· 4 shared A. Riva· 3 shared J. Li· 3 shared R. L. Bennett· 3 shared A. Sobh· 2 shared B. G. Barwick· 2 shared L. H. Boise· 2 shared M. Kulis· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. D. Licht

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells

C. Kasap, A. Izgutdina, B. Patino-Escobar, A. Kang, N. Chilakapati, N. Akagi, H. Johnson, T. Rashid, J. Werner, A. Barpanda, H. Geng, Y.-H. T. Lin, S. Rampersaud, D. Gil-Alos, A. Sobh, , A. Wiita

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

bioRxiv · Feb 24, 2024Cancer Biology

KDM6A Regulates Immune Response Genes in Multiple Myeloma

D. Dupere-Richer, A. Riva, S. Maji, B. G. Barwick, H. Casella, A. Sobh, G. Quickstad, J. Li, u. de, C. Piper, M. Kulis, T. Ezponda, I. Martin-Subero, G. Tonon, W. Zhang, , J. D. Licht

This study shows KDM6A regulates immune response genes in multiple myeloma by activating NLRC5 and CIITA, and its loss reduces MHC expression, which can be reversed by HDAC3 inhibitors.

bioRxiv · Feb 12, 2024Cancer Biology

HDAC8-mediated inhibition of EP300 drives a neural crest-like transcriptional state that increases melanoma brain metastasis

M. F. Emmons, R. L. Bennett, A. Riva, C. Zhang, R. Macaulay, D. Dupere-Richer, B. Fang, E. Seto, J. Koomen, J. Li, A. Chen, P. Forsyth, J. Licht, K. S. M. Smalley

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks

K. Venugopal, P. Nowialis, Y. Feng, D. E. Shabashvili, C. M. Berntsen, K. I. Krajcik, C. Taragjini, Z. Zaroogian, H. L. Casellas-Roman, L. M. Posada, C. Gunaratne, J. Li, D. Dupere-Richer, R. L. Bennett, S. Pondugula, , O. A. Guryanova

This study shows that DNMT3A mutations impair replication fork recovery, leading to DNA damage and sensitivity to nucleoside analogs like cytarabine.

bioRxiv · May 28, 2021Cancer Biology

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

R. Ordonez, M. Kulis, N. Russinol, V. Chapaprieta, R. Beekman, C. Meydan, M. Duran-Ferrer, N. Verdaguer-Dot, G. Clot, R. Vilarrasa-Blasi, L. Garate, E. Miranda, A. Carrasco, T. Ezponda, A. Vilas-Zornoza, , J. I. Martin-Subero

The paper identifies aberrant chromatin activation as a common mechanism driving the malignant phenotype in multiple myeloma.

bioRxiv · Aug 20, 2019Cancer Biology